๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

P-492 A multicenter, open-label, phase Ilia trial of erlotinib in patients with advanced non-small cell lung cancer

โœ Scribed by Hainsworth, J.; Spigel, D.; O'Neill, V.; Klencke, B.

Book ID
118573397
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
148 KB
Volume
49
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Final survival and safety results from a
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
โœ David R. Spigel; Ming Lin; Vincent O'Neill; John D. Hainsworth ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR) with a proven survival advantage for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who have failed a prior chemotherapy. This phase 3b, mult